Evidence map›Paper›PMID 38472478›Full record

ArticleLeukemia2024

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.

Daniela Žáčková, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Daniela Žáčková *Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic. Zackova.daniela@fnbrno.cz.ORCID 0000-0001-9802-8148
Lukáš Semerád *Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Edgar FaberDpt. of Hemato-oncology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic.
Hana KlamováInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
Lukáš StejskalDpt. of Hemato-oncology, University Hospital Ostrava and Ostrava University, Ostrava, Czech Republic.
Petra Bělohlávková4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic.
Michal KarasDpt. of Hemato-oncology, University Hospital Plzeň and Charles University, Plzeň, Czech Republic.
Eduard Cmunt1st Dpt. of Internal Medicine - Hematology, General University Hospital, Prague, Czech Republic.
Olga ČernáDpt. Of Hematology, University Hospital Královské Vinohrady and Charles University, Prague, Czech Republic.
Jiřina ProcházkováDpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Petra ČičátkováDpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Anežka KvetkováDpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Tomáš HorňákDpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.ORCID 0000-0002-7003-3372
Ivana SkoumalováDpt. of Hemato-oncology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic.
Dana SrbováInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
Cyril ŠálekInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.ORCID 0000-0002-0021-3247
David BuffaDpt. of Hemato-oncology, University Hospital Ostrava and Ostrava University, Ostrava, Czech Republic.
Jaroslava Voglová4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic.
Tomáš JurčekDpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Adam FoltaDpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Ivana JežíškováDpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Hana ŽižkováInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
Kateřina Machová PolákováInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
Tomáš PapajíkDpt. of Hemato-oncology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic.
Pavel Žák4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic.
Pavel JindraDpt. of Hemato-oncology, University Hospital Plzeň and Charles University, Plzeň, Czech Republic.ORCID 0000-0002-8415-7069
Adam SvobodníkDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Radka ŠtěpánováDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Jiří MayerDpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.ORCID 0000-0003-0567-9887

Funding

Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic) NU22-03-00136
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, MyeloidChronic DiseaseCzech RepublicHumansProtein Kinase InhibitorsTyrosine Kinase InhibitorsProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Identifiers

PMID38472478
PMCPMC10997522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.